184 related articles for article (PubMed ID: 25532410)
1. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
2. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
Wang LX; Xie YM; Ai QH; Xu WF
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
[TBL] [Abstract][Full Text] [Related]
3. [Apply association rules to analysis adverse drug reactions of shuxuening injection based on spontaneous reporting system data].
Yang W; Xie YM; Xiang YY
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3616-20. PubMed ID: 25532406
[TBL] [Abstract][Full Text] [Related]
4. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
5. [Spontaneous reportintg system data based on shuxuetong injection adverse reactions signal warning analysis].
Jiang JJ; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2994-7. PubMed ID: 24471318
[TBL] [Abstract][Full Text] [Related]
6. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
7. [Systematic analysis on clinical safety of Shuxuetong injection].
Guo XF; Wen ZH; Xie YM; Liu SN; Li ZY; Chen DC
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2782-5. PubMed ID: 23285933
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
9. [Necessity of applying pharmacovigilance in post-marketing safety monitoring of traditional Chinese medicine injections].
Wang HN; Chen W; Fu Z; Du WM; He J
Zhongguo Zhong Yao Za Zhi; 2008 Mar; 33(5):612-4. PubMed ID: 18536393
[TBL] [Abstract][Full Text] [Related]
10. [Post-marketing surveillance of
Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
[No Abstract] [Full Text] [Related]
11. [Analysis suspected allergic factors to shenqi fuzheng injection based on prescription sequence analysis and nested case control study].
Ai QH; Zeng XB; Xie YM; Yang W
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3563-6. PubMed ID: 25532396
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
13. [Impact analysis of shenqi fuzheng injection of course on liver function based on hospital information system data].
Ai QH; Xie YM; You L; Li YY; Yang W
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3606-8. PubMed ID: 25532404
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
15. [Post-marketing clinical safety assessment of Shenmai injection based on active monitoring and passive monitoring in large data background].
Wang LX; Xie YM; Ai QH; Song NB
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4752-6. PubMed ID: 27245017
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
[TBL] [Abstract][Full Text] [Related]
18. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
19. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations.
Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Cheng JQ
Biomed Pharmacother; 2019 Jan; 109():1523-1531. PubMed ID: 30551404
[TBL] [Abstract][Full Text] [Related]
20. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
